You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 10,077,280


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,077,280
Title:Mixed ligand gold(I) complexes as anti-cancer agents
Abstract: Gold(I) complex with mixed ligands as an anticancer agent. The gold(I) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g. phosphines). Also described are a pharmaceutical composition incorporating the gold(I) complex, a methods of synthesizing the gold(I) complex, and a method for treating cancer.
Inventor(s): Al-Jaroudi; Said S. (Dhahran, SA), Alhoshani; Ali (Riyadh, SA), Altaf; Muhammad (Dhahran, SA), Isab; Anvarhusein Abdulkadir (Dhahran, SA)
Assignee: King Fahd University of Petroleum and Minerals (Dhahran, SA) King Saud University (Riyadh, SA)
Application Number:15/351,585
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,077,280

Introduction

When analyzing the claims and patent landscape of a specific patent, such as United States Patent 10,077,280, it is crucial to consider several key factors, including the patent's claims, the relevant legal and regulatory environment, and the broader patent landscape. Here, we will delve into these aspects to provide a comprehensive and critical analysis.

Understanding the Patent Claims

To begin, it is essential to scrutinize the claims of the patent in question. The claims define the scope of the invention and are critical in determining the patent's validity and enforceability.

Claim Construction

Claim construction involves interpreting the language of the claims to understand what the patent covers. This process is often contentious and can be a focal point in patent litigation. For example, the USPTO's updated guidance on AI patents emphasizes the importance of evaluating whether a claim integrates a judicial exception into a practical application, which can significantly impact claim construction[2].

Claim Validity

The validity of the claims can be challenged through various mechanisms, such as ex parte reexamination or inter partes review. The Federal Circuit has established that the validity of claims must be assessed based on the adjusted expiration date of the patent, including any Patent Term Adjustment (PTA)[1].

Legal and Regulatory Environment

The legal and regulatory framework governing patents in the United States is complex and evolving.

Patent Term Adjustment (PTA)

PTA is a critical factor in determining the expiration date of a patent. The Federal Circuit has ruled that ODP (Obviousness-Type Double Patenting) analyses should be based on the adjusted expiration date of the patent, including any PTA granted due to USPTO delays during prosecution[1].

Subject Matter Eligibility

The USPTO's recent guidance updates, particularly those related to AI patents, highlight the importance of subject matter eligibility. The guidance clarifies that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution and the claimed invention offers a concrete technological improvement[2].

Recent Case Law and Guidance

The integration of recent Federal Circuit decisions into USPTO guidance ensures consistency and clarity in the application of patent eligibility criteria. For instance, the updated guidance includes examples specifically tailored to AI technologies, illustrating how claims involving AI can meet eligibility criteria[2].

Patent Assertion Entities (PAEs)

PAEs, also known as patent trolls, play a significant role in the patent landscape and can impact the enforcement and value of patents.

Types of PAEs

There are two primary models of PAE behavior: Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses covering large portfolios without initially suing, generating significant revenue. Litigation PAEs, on the other hand, typically sue potential licensees and settle quickly, often engaging in nuisance litigation[3].

Impact on Patent Landscape

PAEs can influence the patent landscape by asserting patents against a wide range of industries, including retail trade. Their activities can lead to significant litigation costs and may not always align with the original intent of patent protection[3].

Patent Quality and Examination Process

The quality of patents and the efficiency of the examination process are vital for maintaining a healthy patent system.

Defining Patent Quality

The Government Accountability Office (GAO) has recommended that the USPTO more consistently define patent quality and articulate this definition in agency documents and guidance. This includes reassessing the time allotted for examination and analyzing the effects of incentives on patent quality[4].

Examination Outcomes

Studies have shown that the allowance rate for patent applications has decreased over time, particularly in fields like drugs and medical instruments, and computers and communications. Only about 55.8% of applications emerge as patents without using continuation procedures[5].

Case Law and Judicial Precedents

Judicial decisions significantly shape the patent landscape and can impact the validity and enforceability of patents.

ODP and Terminal Disclaimers

The Federal Circuit has clarified that ODP analyses and terminal disclaimers should be considered after any PTA. This ensures that the adjusted expiration date of the patent is the basis for such analyses, preventing an inventor from securing a second, later-expiring patent for the same invention[1].

AI Patent Eligibility

Recent case law integrated into USPTO guidance emphasizes that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated fairly[2].

Practical Applications and Real-World Impact

The practical applications and real-world impact of a patent are crucial in determining its value and relevance.

Real-World Applications

For a patent to be eligible, it must demonstrate a practical application that provides concrete benefits or solves specific problems in the relevant field. For example, a claim involving an artificial neural network must show how it improves computer technology or provides a practical application[2].

Economic Impact

The economic impact of patents, including those asserted by PAEs, can be significant. Portfolio PAEs generate substantial revenue through licensing large portfolios, while Litigation PAEs may engage in activities that are more akin to nuisance litigation, affecting various industries[3].

Key Takeaways

  • Claim Construction and Validity: The claims of a patent must be carefully constructed and validated to ensure they meet legal and regulatory standards.
  • Legal and Regulatory Environment: The patent landscape is influenced by evolving legal and regulatory frameworks, including updates on AI patents and PTA.
  • PAEs: PAEs play a significant role in patent enforcement and can impact the value and enforcement of patents.
  • Patent Quality: Ensuring high patent quality through rigorous examination processes is essential for maintaining a healthy patent system.
  • Judicial Precedents: Case law and judicial decisions are critical in shaping the patent landscape and determining the validity and enforceability of patents.
  • Practical Applications: Patents must demonstrate practical applications that provide concrete benefits to be considered eligible.

FAQs

  1. What is the significance of Patent Term Adjustment (PTA) in patent validity? PTA is crucial as it affects the expiration date of a patent. The Federal Circuit has ruled that ODP analyses should be based on the adjusted expiration date, including any PTA granted due to USPTO delays[1].

  2. How do PAEs impact the patent landscape? PAEs can significantly impact the patent landscape by asserting patents against various industries, leading to substantial litigation costs and potentially engaging in nuisance litigation[3].

  3. What are the key factors in determining patent eligibility for AI-related inventions? The key factors include evaluating whether the claim integrates a judicial exception into a practical application and demonstrating that the claimed invention offers a concrete technological improvement[2].

  4. What is the current allowance rate for patent applications in the US? Only about 55.8% of patent applications emerge as patents without using continuation procedures, with the allowance rate decreasing over time, especially in certain fields[5].

  5. How does recent case law influence the patent eligibility of AI-assisted inventions? Recent case law integrated into USPTO guidance ensures that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution and the claimed invention offers a concrete technological improvement[2].

Sources

  1. In re Cellect - United States Court of Appeals for the Federal Circuit[1]
  2. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz[2]
  3. Patent Assertion Entity Activity: An FTC Study - Federal Trade Commission[3]
  4. Intellectual Property: Patent Office Should Define Quality, Reassess ... - Government Accountability Office[4]
  5. What Is the Probability of Receiving a US Patent? - Yale Journal of Law & Technology[5]

More… ↓

⤷  Subscribe

Details for Patent 10,077,280

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 10,077,280 2036-04-22
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,077,280 2036-04-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 10,077,280 2036-04-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 10,077,280 2036-04-22
Eli Lilly And Company ERBITUX cetuximab Injection 125084 February 12, 2004 10,077,280 2036-04-22
Eli Lilly And Company ERBITUX cetuximab Injection 125084 March 28, 2007 10,077,280 2036-04-22
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 10,077,280 2036-04-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.